{"id":49436,"date":"2022-10-10T17:02:03","date_gmt":"2022-10-10T15:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/"},"modified":"2022-10-10T17:02:03","modified_gmt":"2022-10-10T15:02:03","slug":"klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/","title":{"rendered":"Klebsiella Infections Drug Research Report 2022: Pipeline Product Profiles, Therapeutic Assessment, Inactive Drugs, Unmet Needs &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5456982\/klebsiella-infections-pipeline-insight-2022?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=njnbn8&amp;utm_campaign=1760332+-+Klebsiella+Infections+Drug+Research+Report+2022%3A+Pipeline+Product+Profiles%2C+Therapeutic+Assessment%2C+Inactive+Drugs%2C+Unmet+Needs&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Klebsiella infections &#8211; Pipeline Insight, 2022&#8221;<\/a> drug pipelines has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221010005509\/en\/1596807\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221010005509\/en\/1596807\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Klebsiella infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n<p>\nThe report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Klebsiella infections pipeline landscape is provided which includes the disease overview and Klebsiella infections treatment guidelines. The assessment part of the report embraces, in depth Klebsiella infections commercial assessment and clinical assessment of the pipeline products under development.\n<\/p>\n<p>\nIn the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Klebsiella infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.\n<\/p>\n<p>\nThe companies and academics are working to assess challenges and seek opportunities that could influence Klebsiella infections R&amp;D. The therapies under development are focused on novel approaches to treat\/improve Klebsiella infections.\n<\/p>\n<p>\n<strong>Klebsiella infections Emerging Drugs Chapters<\/strong>\n<\/p>\n<p>\nThis segment of the Klebsiella infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.\n<\/p>\n<p>\n<strong>Klebsiella infections Emerging Drugs<\/strong>\n<\/p>\n<p>\n<strong>Kleb4V: LimmaTech Biologics<\/strong>\n<\/p>\n<p>\nLimmaTech Biologics is developing Klebsiella pneumoniae tetravalent bioconjugate vaccine. LimmaTech Biologics uses a proprietary in vivo enzyme-based production method that alleviates the issues associated with the chemical conjugation process. At the core of this approach is a bacterial enzyme capable of forming precise linkages between glycan and protein moieties.\n<\/p>\n<p>\nThe versatility of this platform combined with our extensive glycoengineering experience enables the development of innovative vaccines for multiple pathogens that has not been possible previously. Kleb4V is currently in Phase I\/II stage of development.\n<\/p>\n<p>\n<strong>Klebsiella infections: Therapeutic Assessment<\/strong>\n<\/p>\n<p>\nThis segment of the report provides insights about the different Klebsiella infections drugs segregated based on following parameters that define the scope of the report, such as:\n<\/p>\n<p>\n<strong>Major Players in Klebsiella infections<\/strong>\n<\/p>\n<p>\nThere are approx. 10+ key companies which are developing the therapies for Klebsiella infections. The companies which have their Klebsiella infections drug candidates in the most advanced stage, i.e. phase I\/II include, LimmaTech Biologics.\n<\/p>\n<p>\n<strong>PhasesThe report covers around 10+ products under different phases of clinical development like<\/strong>\n<\/p>\n<ul>\n<li>\nLate stage products (Phase III)\n<\/li>\n<li>\nMid-stage products (Phase II)\n<\/li>\n<li>\nEarly-stage product (Phase I) along with the details of\n<\/li>\n<li>\nPre-clinical and Discovery stage candidates\n<\/li>\n<li>\nDiscontinued &amp; Inactive candidates\n<\/li>\n<li>\nRoute of Administration\n<\/li>\n<\/ul>\n<p>\n<strong>Products have been categorized under various ROAs such as<\/strong>\n<\/p>\n<ul>\n<li>\nOral\n<\/li>\n<li>\nParenteral\n<\/li>\n<li>\nintravenous\n<\/li>\n<li>\nSubcutaneous\n<\/li>\n<li>\nTopical\n<\/li>\n<li>\nMolecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>Products have been categorized under various Molecule types such as<\/strong>\n<\/p>\n<ul>\n<li>\nMonoclonal Antibody\n<\/li>\n<li>\nPeptides\n<\/li>\n<li>\nPolymer\n<\/li>\n<li>\nSmall molecule\n<\/li>\n<li>\nGene therapy\n<\/li>\n<li>\nProduct Type\n<\/li>\n<\/ul>\n<p>\n<strong>Klebsiella infections Report Assessment<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Product Profiles\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nPipeline Assessment\n<\/li>\n<li>\nInactive drugs assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<\/ul>\n<p>\n<strong>Key Players<\/strong>\n<\/p>\n<ul>\n<li>\nLimmaTech Biologics\n<\/li>\n<li>\nC3J Therapeutics\n<\/li>\n<li>\nNosopharm\n<\/li>\n<li>\nPhico Therapeutics\n<\/li>\n<li>\nLocus Biosciences\n<\/li>\n<li>\nAKTHELIA\n<\/li>\n<li>\nAppili Therapeutics\n<\/li>\n<li>\nDebiopharm\n<\/li>\n<li>\nAffinivax\n<\/li>\n<li>\nNomad Bioscience\n<\/li>\n<\/ul>\n<p>\n<strong>Key Products<\/strong>\n<\/p>\n<ul>\n<li>\nKleb4V\n<\/li>\n<li>\nASP 1004\n<\/li>\n<li>\nNOSO-502\n<\/li>\n<li>\nLBP-KP01\n<\/li>\n<li>\nATI-1503\n<\/li>\n<li>\nDebio 1454\n<\/li>\n<li>\nResearch programme: Klebsiella and Pseudomonas vaccines\n<\/li>\n<li>\nResearch programme: antibacterial biologics\n<\/li>\n<\/ul>\n<p>\nFor more information about this drug pipelines report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5456982\/klebsiella-infections-pipeline-insight-2022?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=njnbn8&amp;utm_campaign=1760332+-+Klebsiella+Infections+Drug+Research+Report+2022%3A+Pipeline+Product+Profiles%2C+Therapeutic+Assessment%2C+Inactive+Drugs%2C+Unmet+Needs&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/m2ff13<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"mailto&#58;&#112;&#114;&#101;&#115;&#115;&#64;&#x72;&#x65;&#x73;&#x65;&#x61;&#x72;&#x63;&#x68;&#x61;&#x6e;&#x64;&#x6d;arkets&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#114;e&#x73;&#115;&#64;&#x72;&#101;s&#x65;&#97;r&#x63;&#104;a&#x6e;&#100;m&#x61;&#114;k&#x65;&#116;s&#x2e;&#99;o&#x6d;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Klebsiella infections &#8211; Pipeline Insight, 2022&#8221; drug pipelines has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Klebsiella infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49436","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Klebsiella Infections Drug Research Report 2022: Pipeline Product Profiles, Therapeutic Assessment, Inactive Drugs, Unmet Needs - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Klebsiella Infections Drug Research Report 2022: Pipeline Product Profiles, Therapeutic Assessment, Inactive Drugs, Unmet Needs - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Klebsiella infections &#8211; Pipeline Insight, 2022&#8221; drug pipelines has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Klebsiella infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-10T15:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221010005509\/en\/1596807\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Klebsiella Infections Drug Research Report 2022: Pipeline Product Profiles, Therapeutic Assessment, Inactive Drugs, Unmet Needs &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-10-10T15:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/\"},\"wordCount\":630,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005509\\\/en\\\/1596807\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/\",\"name\":\"Klebsiella Infections Drug Research Report 2022: Pipeline Product Profiles, Therapeutic Assessment, Inactive Drugs, Unmet Needs - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005509\\\/en\\\/1596807\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-10-10T15:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005509\\\/en\\\/1596807\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005509\\\/en\\\/1596807\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Klebsiella Infections Drug Research Report 2022: Pipeline Product Profiles, Therapeutic Assessment, Inactive Drugs, Unmet Needs &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Klebsiella Infections Drug Research Report 2022: Pipeline Product Profiles, Therapeutic Assessment, Inactive Drugs, Unmet Needs - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Klebsiella Infections Drug Research Report 2022: Pipeline Product Profiles, Therapeutic Assessment, Inactive Drugs, Unmet Needs - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Klebsiella infections &#8211; Pipeline Insight, 2022&#8221; drug pipelines has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Klebsiella infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-10T15:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221010005509\/en\/1596807\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Klebsiella Infections Drug Research Report 2022: Pipeline Product Profiles, Therapeutic Assessment, Inactive Drugs, Unmet Needs &#8211; ResearchAndMarkets.com","datePublished":"2022-10-10T15:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/"},"wordCount":630,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221010005509\/en\/1596807\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/","name":"Klebsiella Infections Drug Research Report 2022: Pipeline Product Profiles, Therapeutic Assessment, Inactive Drugs, Unmet Needs - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221010005509\/en\/1596807\/21\/logo.jpg","datePublished":"2022-10-10T15:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221010005509\/en\/1596807\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221010005509\/en\/1596807\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/klebsiella-infections-drug-research-report-2022-pipeline-product-profiles-therapeutic-assessment-inactive-drugs-unmet-needs-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Klebsiella Infections Drug Research Report 2022: Pipeline Product Profiles, Therapeutic Assessment, Inactive Drugs, Unmet Needs &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49436"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49436\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}